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Background: Since oocyte donors are typically young and believed to be a source of highly competent gametes, donor
oocyte IVF is considered to be an effective treatment for diminished ovarian reserve. However, the aneuploidy rate for
embryos originating from anonymously donated oocytes remains incompletely characterized. Here, comprehensive
chromosomal screening results were reviewed from embryos obtained from anonymous donor-egg IVF cycles to
determine both the aneuploidy rate and parental source of the genetic error. To measure this, preimplantation genetic
screening (PGS) data on embryos were retrospectively collated with parental DNA obtained before IVF for
chromosome-specific assessments. This approach permitted mitotic and meiotic copy errors to be differentiated for
each chromosome among all embryos tested, thus providing information on the parental source of embryo
aneuploidy (i.e., from the anonymous egg donor vs. sperm source).
Results: 305 embryos generated for 24 patients who began IVF treatment in 2013. For oocyte donors (n = 24), mean
(±SD) age was 24.0 ± 2.7 years (range = 20-29). For embryos with full chromosomal reporting (n = 284), euploidy was
present in only 133 (46.8%). Considering all embryo chromosomes, the average error rate was 18%. 133 of 151
observed embryo aneuploidies (88.1%) were attributable to an oocyte donor source. Among all aneuploid embryos
(n = 151), chromosomal errors from both genetic parents (i.e., oocyte donor and sperm source) were present in 57%.
The average correlation coefficient across all pairs of chromosomal abnormalities (r = 0.60) suggests that chromosomes
tend to have multiple and simultaneous errors (complex aneuploidy) even when oocytes from young donors are used.
Conclusion: These data show that even when young donors provide oocytes for IVF, the probability of embryo
aneuploidy remains high. The oocyte donor appears to make an important contribution to embryo aneuploidy even
when her age is <30 yrs. If these findings are confirmed with larger, prospective studies, the routine integration of PGS
with donor oocyte IVF cycles to identify single euploid embryos for transfer should be considered.Background
Embryo aneuploidy is among the most important contrib-
utors to poor outcomes observed with in vitro fertilization
(IVF). Numerous investigators have independently con-
cluded that human embryos intrinsically contain substan-
tial chromosomal error [1-3] and that this problem is* Correspondence: sillsivf@havingbabies.com
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unless otherwise stated.more pronounced as maternal age increases. Accordingly,
preimplantation testing of embryos obtained from IVF pa-
tients at age ≥35 can be helpful to improve efficiency of
infertility treatment. Nevertheless, oocyte donation with
IVF remains a commonly applied method of assisted
reproduction for this group of older patients [4]. The
therapeutic intervention of oocyte donation with IVF is
believed to be so successful largely because oocyte quality
is greatly improved when the donor’s age is low, thus
yielding better pregnancy rates and reduced miscarriage
risk.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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onymous donors, how low does the chromosomal error
rate actually go? This question has already been partially
explored when a limited number of chromosomes were
studied in embryos obtained from donor-egg IVF treat-
ment, and the aneuploidy rate (even in that partial genomic
assessment) was higher than expected [5]. From this earlier
pioneering work, our study reviewed preimplantation gen-
etic screening (PGS) data in the context of anonymous
donor oocyte IVF. Using increased bandwidth to capture
comprehensive chromosomal screening data on all 23 pairs
of chromosomes, this investigation aimed to answer two
unresolved issues: 1) What is the actual incidence of genetic
abnormality in embryos produced from anonymously do-
nated oocytes, and 2) Did the embryo ploidy error originate
from the sperm of the recipient’s partner, or the oocyte of
the anonymous donor?Results
During the 12 month review period ending December
2013, a total of 676 IVF cases proceeded to oocyte re-
trieval at this unit. Of these, 50 were anonymous oocyte
donors undergoing ovum pick-up. A total of 428 patients
requested PGD during the study interval. Intersecting
these two patient sub-sets identified 24 IVF cases which
included both anonymous oocyte donation and PGS (see
Figure 1). Analysis of this group revealed that 305 em-
bryos underwent biopsy and full molecular karyotyping.
The mean (±SD) age of recipient females in this study
population was 42.5 ± 4.0 (range 35-52) years. Mean
(±SD) age was 24.0 ± 2.7 (range 20-29) years for oocyte
donors (n = 24).Figure 1 To determine frequency and source of chromosomal
error in “good prognosis” IVF cases, embryos (n = 305) from
patients undergoing both anonymous donor oocyte IVF and
PGS of embryos were subjected to comprehensive
chromosomal screening.The partners of the intended parents had a mean (±SD)
age of 44.3 ± 7.1 (range 25-58 years). Average sperm con-
centration and motility were 52.8 M/mL (range 2.4-
135 M/mL) and 40.8% (range 2-81%), respectively.
In this study group, the mean (±SD) number of oocytes
which underwent ICSI was 17.7 ± 7.8 (range = 6-35), and
this yielded an average of 15.1 ± 6.7 2pn zygotes per pa-
tient (range = 6-32). Most embryos (86%) were biopsied
on day three, while the remainder (14%) were biopsied on
day five. Although the number of blastocyst biopsies was
relatively small (n = 44), it was possible to record embryo
ploidy as a function of biopsy timing. Using this approach,
we found the incidence of missed calls (“no signal”) on
chromosomes to be significantly higher among embryos
biopsied at day three, resulting in reduced reporting effi-
ciency for this group compared to the blastocyst biopsy
group (92 vs. 100%; p = 0.05).
Assessment of all embryos produced from oocytes con-
tributed by an anonymous donor identified euploidy in
133 of 284 (46.8%) of embryos with full chromosomal
reporting (i.e. zero “no calls”). Complete data on all 23
chromosome pairs was reported for 93.1% of embryos
sampled (284 of 305). Considering all embryo chromo-
somes, mean error rate was 18%. A chromosome-specific
analysis found some error in each chromosome, but
chromosome 22 was most often affected. In contrast,
chromosome 15 was the least likely to have an abnormal-
ity in this population (see Figure 2). The relatively high
Phi correlation coefficients (see Figure 3) among embryo
chromosome pairs with aneuploidy (r = 0.60, range 0.42-
0.77; p < 0.01 by Chi-square test) indicates that chromo-
somes tend to have multiple and simultaneous errors
(complex aneuploidy).
When analysis was confined only to those embryos
with no missed calls for any chromosome, errors attrib-
utable to a maternal source (i.e., from the oocyte donor)
were noted in 133 of 284 embryos (46.8%). Conversely,
an embryo genetic abnormality of paternal origin was
present in 104 of 284 embryos (36.6%). Among all aneu-
ploid embryos (n = 151), chromosomal errors from both
genetic parents (i.e., oocyte donor and sperm source)
were present in 57.0% (see Figure 4). While oocyte
donor age ranged from 20-29 years, some genetically ab-
normal embryos were produced from donors of each age
and there was no correlation between oocyte donor age
and embryo aneuploidy. Likewise, these data did not
confirm a correlation between embryo aneuploidy and
male partner age or any semen parameter.
Discussion
The arrival of oocyte donation preceded PGS in clinical
practice, and was originally offered as a treatment for
premature ovarian failure or oophorectomy [6]. Egg do-
nation is now commonly in use for many settings
Figure 2 Distribution of aneuploidy as a function of specific chromosomal error measured in embryos (n = 305) produced from
anonymous donor oocyte IVF cycles. All chromosomes demonstrated some ploidy error in this study, although chromosome 15 and
chromosome 22 (red circles) were found to have the highest and lowest rates of abnormality, respectively.
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circumvent transmission of severe genetic disorder(s) in
the birth mother to her offspring [7]. While the corro-
sive effect of age on female infertility can be successfully
assuaged by use of oocytes donated by a younger (pre-
sumably more fertile) woman [8], the benefit of this
“genetic rescue” is difficult to calibrate in clinical prac-
tice. Of note, the degree of aneuploidy in embryos de-
rived from egg donation was surprisingly high when






















Figure 3 Pairwise correlations of autosomal aneuploidy by mean squ
derived from anonymous donor oocyte IVF treatments) reveal a wideA recent retrospective study covering 12 years of data
collected from anonymous oocyte donor applicants
found that genetic abnormalities resulted in a significant
number of candidates being rendered ineligible to par-
ticipate in their oocyte donor program [9]. We agree
with such screening, and, like many institutions, require
any potential anonymous oocyte donor to first undergo
a careful genetic testing regime before entering the ros-
ter of active oocyte donors. Indeed, all of the anonymous










are contingency (Phi) coefficient (observed in 305 embryos
distribution of error among all chromosomes.
Figure 4 In this investigation, most embryos contained chromosomal error contributed by both genetic parents. However, the
anonymous oocyte donor was responsible for a greater number of chromosomal abnormality compared to the sperm source. Here, distribution
of aneuploidy origin (by gamete source) for embryos produced from anonymous donor oocyte IVF is summarized.
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ders in advance of their accession into our egg donor
group. However, despite this reassuring clearance (and
in the absence of any obvious reproductive pathology)
the rate of chromosomal error among embryos produced
from their eggs was still 55%.
Previous research has attempted to characterize the
role of “defective” gametes resulting in generation of ab-
normal embryos using an egg-sharing model, where one
IVF patient agrees to share her eggs with another IVF
patient [10]. It is unclear if this treatment strategy is
ideal for the poor prognosis IVF patient, since what she
ultimately gets is simply bad eggs from another infertility
patient. Such a study is unsatisfying experimentally be-
cause the variable of oocyte pathology cannot be con-
trolled if all oocytes are generated by other patients with
a variety of infertility diagnoses.
Enhanced clarity on this issue was provided when an-
euploidy rate for eight chromosomes in embryos derived
from young (<35 yrs) oocyte donors using fluorescence
in-situ hybridization analysis was studied. Using this ap-
proach, all oocytes were provided by healthy women
who did not have any infertility diagnosis. The authors
reported considerable variation between donor cycles
with nearly one-third having <30% genetically normal
embryos [5]. Starting from these data where less than
half of the embryo’s chromosomes had been evaluated,
our work built on this foundation to screen all 23 pairs
of embryo chromosomes in an anonymous donor oocyte
IVF setting. Importantly, since behavior of each parental
allelic group is a function of the underlying chromosome
copy number of the embryo, and because these modifi-
cations may be satisfactorily estimated from additionalallelic content contributed by (or omitted from) either
the oocyte donor or the sperm source, we were able to
supply additional information on the parental origin of
the genetic problems identified in the embryos derived
therefrom.
Earlier research has shown a significantly higher ob-
served pregnancy loss rate among IVF patients with age
≥40 compared to women younger than age 40 [11], es-
tablishing that the distribution of genetic error in em-
bryos is a function of maternal age. This physiologic
process of natural ovarian senescence has been side-
stepped for many years by using oocytes provided by
younger donors [12]. With further refinement of donor
oocyte protocols, acceptance of this treatment in routine
IVF practice has increased greatly over the last decade,
and when donor oocytes are used the likelihood of an
excellent IVF outcome seems independent of recipient
age [13]. In the United States, the incidence of twins is
markedly higher among anonymous oocyte donor IVF
cycles compared to IVF using native (autologous) oo-
cytes (37 vs. 29%, respectively), which provides direct
evidence that most clinics are not following a current
recommendation by the American Society for Repro-
ductive Medicine which encourages single embryo trans-
fers when oocyte donor age is young [14]. Moreover,
there is international consensus that elective single em-
bryo transfers are appropriate for oocyte donor-recipient
cycles where the donor has good prognosis and when
good quality embryos are available [15].
Until now, comprehensive chromosomal screening has
not been applied to embryos of donor oocyte origin to
quantify the level of genetic abnormality present in such
embryos. If ever the domain of anonymous donor oocyte
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bryo aneuploidy could be dismissed as unimportant, the
current study suggests otherwise and highlights an im-
portant supporting role for PGS in this setting. But the
basic assumption that preimplantation embryo testing
adds diagnostic value to any IVF patient or that this reli-
ably improves reproductive outcomes has not been with-
out challenge [16,17]. Particularly when preimplantation
genetic assessment evaluates only a limited number of
embryo chromosomes, the process has been derided as
“…the first ever widely introduced routine IVF practice
which actually harmed IVF cycle outcomes” [18].
While more data are needed to settle this debate, our
study does contribute some new observations on human
embryo genetics. Here, we focused on the specific topic
of parental origin with respect to chromosomal errors
harbored by IVF embryos. Our observation that a high
rate of embryonic genetic anomaly could be traced back
to the oocyte donor was not anticipated. Thus, even
when the age of the oocyte source is low, the traditional
view that most chromosomal errors are of maternal ori-
gin caused by malsegregation in the first meiotic division
[19] appears to remain valid.
Our report has some limitations which should be ac-
knowledged. Our data come from a retrospective ana-
lysis as an initial step to analyze readily accessible
existing data. We aimed to produce a hypothesis about
aneuploidy rate in embryos derived from anonymous
donor oocytes which could then be tested prospectively.
Retrospective work has the potential for incomplete
documentation, unrecoverable or unrecorded data, and
variance in the quality of information recorded. The reli-
ability of data entry is considered high for this sample,
and the proportion of incomplete records was marginal.
Also, because our sample was limited and represented
the chance event of an IVF patient using anonymous
donor oocytes also incorporating pre-implantation test-
ing of embryos produced from this treatment, it is un-
certain if these findings can generalize to all anonymous
donor egg IVF cases. However, a secondary chart review
for our study population did not reveal any obvious
characteristic which may have influenced the patient’s
decision to include PGS in her IVF treatment. Perhaps
the high economic cost of IVF in general [20] (and
donor oocyte treatment in particular) introduced some
“access bias”, as only the most affluent IVF patients
might have been able to afford this particular treatment.
It would be interesting to query the remaining donor oo-
cyte IVF patients in this series who declined PGS (n =
26), to understand better why they decided not to re-
quest genetic testing for their embryos; this represents
an area of future research here. Finally, our analysis of
male factor data was confined to age of the recipient’s
husband and only two semen parameters (spermconcentration and motility). We did not include sperm
DNA fragmentation data in this study, although this has
not yet been correlated with embryo ploidy [21].
Conclusion
IVF with anonymous oocyte donation remains a highly
effective treatment for many patients with low ovarian
reserve. While this approach effects a partial retreat of
the embryo aneuploidy problem, complete surrender
seems impossible—even when oocytes from donors as
young as 20 years of age are used. Further prospective
studies are needed utilizing comprehensive chromo-




This retrospective investigation reviewed selected data
from all in vitro fertilization (IVF) cases at HRC Fertility
(Orange County, Calif.) in 2013 to identify the subset of
patients where PGS was performed on embryos derived
exclusively from anonymous oocyte donors. IRB approval
was sought although the proposal was classified as exempt
because the study reviewed data already collected and no
specific patient identifiers were recorded. PGS results were
collated with parental DNA obtained immediately before
IVF (i.e., from the anonymous egg donor and the sperm
source) for chromosome-specific assessments. This ap-
proach permitted mitotic and meiotic copy errors to be
differentiated for each chromosome among all embryos
tested, thus providing information on the specific parental
source of embryo aneuploidy.
Oocyte donor and patient (recipient) selection
Anonymous oocyte donors had completed comprehensive
medical and psychological evaluation as described previ-
ously [22]. Additionally, donors underwent a genetic
evaluation and were required to have a normal result (no
mutations) on an expanded carrier test [23] before enroll-
ment. Recipients had their initial reproductive endocrin-
ology consultation and monitoring at our facility, and all
baseline laboratory tests were within normal limits. An-
onymous oocyte donor counseling was provided by an
accredited psychologist before starting gonadotropins.
Each recipient selected her anonymous oocyte donor via
secure internet portal with an electronic lock-out mechan-
ism to prohibit multiple recipients from accessing the ag-
gregate donor pool at the same time. A dedicated nurse
coordinator was available to facilitate oocyte donor selec-
tion in all cases. Following registration of each provisional
donor-recipient match, the corresponding anonymous oo-
cyte donor entry was deleted from the donor library, thus
creating a 1:1 ratio for each recipient and their anonymous
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from the same anonymous donor for this analysis).
The anonymous oocyte donor commenced controlled
ovarian hyperstimulation and transvaginal ultrasound-
guided oocyte collection followed 36 h after s.c. hCG ad-
ministration as previously described [24]. Sperm from the
recipient’s partner was used to fertilize all freshly retrieved
eggs obtained from the anonymous oocyte donor; intracy-
toplasmic sperm injection (ICSI) was performed in all
cases.
For all records reviewed for this study, recipient and
(male) partner age were tabulated, as was age of the an-
onymous oocyte donor. Sperm concentration and sperm
motility were calculated as an average of two semen ana-
lyses performed no more than six months before treat-
ment. The following laboratory parameters were also
evaluated: number of oocytes fertilized (via ICSI), number
of two pronuclear (2pn) zygotes produced, number of em-
bryos biopsied, day of biopsy, and number of euploid em-
bryos. In addition, the number and frequency of error
observed in each chromosome was recorded, with refer-
ence to the (genetic) parental origin of the abnormality, as
described previously [25].
Ovarian stimulation and fertilization
Before commencing gonadotropin therapy, oocyte donors
underwent transvaginal ultrasound evaluation with re-
measurement of serum FSH, LH and estradiol on d3 of
the index cycle. Pituitary downregulation was achieved
with GnRH-agonist administered on d21 of the cycle im-
mediately preceding treatment, as previously described
[24]. Periodic transvaginal ultrasound and serum estradiol
measurements were used to track follicular growth and
thickness of endometrial lining. When ≥3 follicles reached
19 mm mean diameter, periovulatory hCG was adminis-
tered by subcutaneous injection of recombinant hCG
(250 μg Ovidrel®, Merck Serono; Geneva, Switzerland)
with oocyte retrieval performed under transvaginal ultra-
sound guidance 35-36 h later. Following removal of all cu-
mulus cells, ICSI was performed and normal fertilization
was verified 16-18 h after injection by presence of two
pronuclei and two polar bodies.
Embryo culture and biopsy
For these embryos, biopsy was performed either on the
morning of day three or at the blastocyst stage (day five).
Biopsy at day three was completed after laser assisted
hatching followed by removal of a single blastomere. Ex-
tended embryo culture occurred in Global single-step
medium (IVF on Line; Guilford, CT) to blastocyst stage.
On d3 when embryos were at the 6–8 cell stage, a Lycos
laser (Hamilton Thorne; Beverly, MA) was used to cre-
ate a circular 6-9 μ diameter opening in the zona pellu-
cida. This breach enabled biopsy of trophectoderm (TE)on d5 rapidly. Between 3–5 herniated TE cells were gen-
tly aspirated by pipette and, when necessary, freed from
the blastocyst by application of laser pulses. Harvested
TE cells were washed in PBS and placed within a PCR
tube with 2.5 μl 1× PBS.Cell isolation, DNA amplification, and genotyping
procedures
Genetic material was obtained from oocyte donors (buccal
swabs), recipient’s husband (peripheral venipuncture), and
embryos (either single-cell day 3 blastomere biopsy or
multi-cell day 5 trophectoderm biopsy). Single tissue cul-
ture (polymorphonuclear leukocytes) and egg donor buc-
cal cells were isolated using a sterile tip attached to a
pipette and stereomicroscope (Leica; Wetzlar, Germany).
For fresh day 3 embryo biopsy, individual blastomeres
were separated via micromanipulator after zona pellucida
hatching by Hamilton-Thorne Lycos laser; a micromanip-
ulator was also used to isolate individual sperm cells. Ex-
cept for sperm, single cells for analysis were washed × 4
with buffer (PBS buffer, pH 7.2; Life Technologies, Carls-
bad CA). Multiple displacement amplification (MDA)
with proteinase K buffer (PKB) was used for this proced-
ure; cells were placed in 5 μl PKB (Arcturus PicoPure
Lysis Buffer, 100 mM DTT, 187.5 mM KCl, 3.75 mM
MgCl2, 3.75 mM Tris-HCl) incubated at 56°C × 1 h,
followed by heat inactivation at 95°C × 10 min and held at
25°C × 15 min. MDA reactions were incubated at 30°C ×
2.5 h and then 65°C × 10 min.
Genomic DNA from buccal tissue was isolated using
the QuickExtract DNA Extract Solution (Epicentre;
Madison WI). Template controls were included for the
amplification method. Amplified single cells and parental
tissue were genotyped using the Infinium II (Illumina; San
Diego, CA) genome wide single nucleotide polymorphism
(SNP) arrays (CytoSNP 12 chip). The standard Infinium II
protocol was used for parent samples and Genome
Studio (http://res.illumina.com/documents/products/tech-
notes/technote_gentrain2.pdf) was used for allele calling.
For single cells, genotyping was accomplished using an
Infinium II genotyping protocol.Establishing copy number and haplotype phasing
Because some commercial software packages use hetero-
zygosity to determine copy number, and high rates of al-
lele drop-out with preferential amplification in single cell
measurements can cause unpredictable heterozygosity (re-
gardless of chromosome copy number), performance is
poor when calling copy number on single cell data. Ac-
cordingly, previous investigators [25] developed a chromo-
some copy number classification algorithm in MATLAB
(MathWorks; Natick, MA), predicated on parental geno-
types and the observed distribution of unprocessed single
Sills et al. Molecular Cytogenetics 2014, 7:68 Page 7 of 8
http://www.molecularcytogenetics.org/content/7/1/68cell microarray channel intensities collated by parental
origin [26,27].
In brief, this approach is based on prior work [25]
whereby the statistical behavior of each parental group dif-
fers as a function of the underlying chromosome copy
number of the embryo. These changes are predictable and
derive from additional allelic content that is contributed by
(or missing from) each parent [25]. Moreover, rank statis-
tics are examined for each parental context and compared
to the expected orderings under the various chromosome
copy number possibilities. Next, the probability is examined
for each parental context that could have swapped rank by
random chance to establish copy number and calculate
confidences [25,28].
Detection of three unmatched haplotypes adds add-
itional confidence to a trisomy call, as many chromosome
copy number errors are meiotic and will be associated
with this configuration. Accordingly, this method included
parental information with high-confidence disomic single
cell measurements on offspring and recombination prob-
abilities to determine the parental chromosome phase. A
maximum likelihood estimator algorithm was used to
phase full chromosomes for all parental genotype con-
texts. Possible haplotypes in single cell measurements are
then evaluated to detect meiotic trisomies.
Segmental copy imbalances were detected by dividing
each chromosome into five segments, with the aforemen-
tioned algorithm applied to each section independently. If
any segments differ in copy number with high confidence,
then the corresponding chromosome is flagged. Note that
the reported copy number for chromosomes with a seg-
mental imbalance is reflective of the call on the majority of
the chromosome, even if part of the chromosome shows
gain or loss. Thus, depending on size, segmental copy im-
balances may reduce composite confidence of the complete
chromosome call. However, confidences on chromosomes
with segmental imbalances may still be high if the deletion
is relatively small and/or the remainder of the chromosome
is called with very high confidence [25].
Individual chromosome means and standard devia-
tions of normalized microarray probe intensities were
used to call chromosome copy number. For each single
cell measurement, a training set of single cell amplifica-
tion microarray measurements was used to normalize
probe intensities across each chromosome. An algorithm
was next used to compute the most likely chromosome
state for all the single cell amplification microarray data.
Statistical analysis
Data were aggregated, analyzed, and visualized with Tab-
leau 8.2 (Tableau Software; Seattle, WA). To estimate a
reference population's aneuploidy rate and the donor (ma-
ternal genetic) aneuploidy contribution, a binomial pro-
portion confidence interval was used on each proportionestimate using the Wald test. When sample size was small
(defined as min[np, n(1-p)] <5), an adjusted Wald method
was used to improve estimation accuracy [29]. For this
analysis, the confidence level was set at 95% by default (90
for aneuploidy rate comparisons). To compare two sample
ratios, the 2-proportion z-test was used for large samples
(defined as min[np, n(1-p)] > =5); Fisher’s exact test was
used when sample size was small.
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